EQUITY RESEARCH - ANALYST MEETING



CHG TB

THAILAND / HEALTH CARE SERVICES

Key takeaways from analyst meeting



UNCHANGED

TARGET PRICE THB3.90 **CLOSE THB2.88 UP/DOWNSIDE** +35.4% PRIOR TP **THB3.90 CHANGE IN TP UNCHANGED** TP vs CONSENSUS +11.2%

Highlights

- We attended CHG's 4Q23 analyst meeting on 8 March and came away with a slightly positive view.
- Management targets revenue growth of 10-15% in 2024 driven by new hospitals, including CHG Mae Sot and CHG Medical Center, international patient revenue, and more SSO registered members.
- Revenue in Jan and Feb has trended positively. Organic revenue had a similar trend in Nov and Dec-23, while revenue from new hospitals should increase compared to the average in 4Q23.
- Management expects the NPM to improve to more than 14% in 2024 (vs 13.5% in 2023), given that most fixed costs were already invested
- For the update on the payment of RW>2 in the Social Security Office (SSO) scheme, CHG already received nine installments in 2023 and is waiting for the last three installments, which management still expects the SSO to pay at a rate of 12,000/RW. CHG also continued to accrue payments at 12,000/RW for treatments in 2024.
- Accounts receivable (AR) outstanding for Covid treatments amounted to THB470m as of 4Q23. CHG expects to finalize these AR with UCEP by this year.

Recommendation

- We forecast core profit to jump 24% to THB1.3b in 2024 on a lower loss from CHG Mae Sot (THB52m loss in 2023 vs THB26m loss in 2024E), the absence of provision expenses related to Covid treatments (THB46m in 2023), THB60m-70m additional core profit growth from a larger SSO registered member base, and organic profit growth of 10-12% from more international patients and the fullyear operation of CHG Medical Center.
- We maintain BUY with a DCF-TP of THB3.9/shr. CHG is trading at an attractive valuation of 24x 2024E P/E.

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	7,730	8,560	9,136	9,749
Net profit	1,046	1,300	1,488	1,632
EPS (THB)	0.10	0.12	0.14	0.15
vs Consensus (%)	-	9.1	12.9	12.8
EBITDA	1,822	2,189	2,438	2,649
Recurring net profit	1,046	1,300	1,488	1,632
Core EPS (THB)	0.10	0.12	0.14	0.15
Chg. In EPS est. (%)	nm	0.0	0.0	nm
EPS growth (%)	(62.4)	24.3	14.5	9.7
Core P/E (x)	30.3	24.4	21.3	19.4
Dividend yield (%)	2.4	2.5	2.8	3.1
EV/EBITDA (x)	17.3	14.2	12.5	11.2
Price/book (x)	4.2	3.9	3.6	3.3
Net debt/Equity (%)	(8.2)	(12.1)	(18.3)	(23.8)
ROE (%)	13.9	16.7	17.7	17.9



Share price performance	1 Month	3 Month	12 Month			
Absolute (%)	(3.4)	(3.4)	(22.6)			
Relative to country (%)	(3.2)	(3.7)	(10.0)			
Mkt cap (USD m)			895			
3m avg. daily turnover (USD m)			2.6			
Free float (%)			43			
Major shareholder	Kannikar Plussind (18%)					
12m high/low (THB)	3.78/2.60					
Issued shares (m)			11,000.00			

Sources: Bloomberg consensus; FSSIA estimates




Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: CHG – 4Q23 results summary

	4Q22	1Q23	2Q23	3Q23	4Q23	Char	nge	2023	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y %)				
Revenue	1,721	1,716	1,799	2,093	2,123	1	23	7,730	(23)
Cost of sales (Incl. depreciation)	(1,229)	(1,276)	(1,380)	(1,486)	(1,580)	6	29	(5,723)	(3)
Gross profit	492	440	418	607	543	(10)	10	2,008	(52)
SG&A	(254)	(200)	(222)	(246)	(243)	(1)	(5)	(911)	(3)
Operating profit	238	240	196	361	300	(17)	26	1,097	(66)
Other operating income	96	73	70	77	65	(15)	(32)	284	(7)
Interest income	2	1	3	1	4	645	114	9	42
Equity income	(1)	(3)	(2)	(5)	(9)	91	696	(19)	0
EBIT	334	309	267	434	361	(17)	8	1,370	(62)
Interest expense	(6)	(4)	(5)	(7)	(9)	27	43	(24)	47
ЕВТ	328	305	262	427	352	(17)	7	1,346	(62)
Income tax	(40)	(60)	(56)	(90)	(73)	(19)	84	(279)	(60)
Minority interests	(3)	(5)	(0)	(11)	(5)	(52)	57	(21)	n/a
Core profit	285	240	206	326	274	(16)	(4)	1,046	(62)
Extraordinaries									
Net income	285	240	206	326	274	(16)	(4)	1,046	(62)
Core EPS (THB)	0.03	0.02	0.02	0.03	0.02	(16)	(4)	0.10	(62)
No of share (m)	11,000	11,000	11,000	11,000	11,000	O	0	11,000	0
Cost (Excl. depreciation)	(1,135)	(1,177)	(1,276)	(1,370)	(1,459)	7	28	(5,282)	(4)
Depreciation & amortisation	(93)	(99)	(104)	(117)	(121)	3	29	(441)	15
EBITDA	427	411	370	554	486	(12)	14	1,822	(54)
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt)
Gross margin	29	26	23	29	26	(3)	(3)	26	(16)
SG&A/Revenue	15	12	12	12	11	(0)	(3)	12	3
EBITDA margin	25	24	21	26	23	(4)	(2)	24	(15)
Net profit margin	17	14	11	16	13	(3)	(4)	14	(14)
Operating stats	(y-y %)								
SSO revenue	(7)	19	23	8	11				
SSO registered members ('000)	520	525	528	529	530				
SSO revenue per head	(17)	10	17	5	8				
Cash-OPD revenue	(38)	(41)	(20)	(6)	24				
Cash-OPD visit number	(5)	(19)	(7)	2	11				
Cash-OPD revenue per head	(34)	(26)	(13)	(8)	12				
Cash-IPD revenue	29	(5)	5	24	22				
Cash-IPD admission number	30	9	30	29	29				

Source: CHG

Exhibit 2: 2024E core profit growth breakdown



Note: Applied 20% tax for each item Source: FSSIA estimates

Exhibit 3: 2024E key earnings growth assumptions

V	A - constitute
Key growth items	Assumptions
Absence of provision expenses	CHG booked provision expenses and a revenue reversal related to Covid treatments totaling THB46m in 2023. We expect no provision expense in 2024.
Turnaround of new hospital	Expect CHG Mae Sot's losses to narrow from THB52m in 2023 to THB26m in 2024.
Additional SSO members	Expect registered members to increase by 50k in 2024 with average revenue per head of THB4,700-4,800 and an EBITDA margin of 34-38% for additional SSO revenue.
Organic growth	Expect core profit growth of 10-12%, driven by higher revenue intensity from International Medical Center and CHG Medical Center.

Source: FSSIA estimates

Financial Statements

Chularat Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	10,103	7,730	8,560	9,136	9,749
Cost of goods sold	(5,908)	(5,723)	(6,212)	(6,544)	(6,933)
Gross profit	4,195	2,008	2,347	2,592	2,815
Other operating income	305	284	295	304	313
Operating costs	(935)	(911)	(957)	(994)	(1,051)
Operating EBITDA	3,947	1,822	2,189	2,438	2,649
Depreciation	(382)	(441)	(503)	(536)	(572)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	3,565	1,381	1,686	1,902	2,078
Net financing costs	(10)	(15)	(12)	3	5
Associates	(1)	(19)	(10)	(4)	1
Recurring non-operating income	(1)	(19)	(10)	(4)	1
Non-recurring items	0	0	0	0	0
Profit before tax	3,554	1,346	1,664	1,901	2,084
Tax	(703)	(279)	(342)	(389)	(426)
Profit after tax	2,850	1,067	1,322	1,512	1,658
Minority interests	(72)	(21)	(22)	(24)	(26)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	2,778	1,046	1,300	1,488	1,632
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	2,778	1,046	1,300	1,488	1,632
Per share (THB)					
Recurring EPS *	0.25	0.10	0.12	0.14	0.15
Reported EPS	0.25	0.10	0.12	0.14	0.15
DPS	0.16	0.07	0.07	0.08	0.09
Diluted shares (used to calculate per share data)	11,000	11,000	11,000	11,000	11,000
Growth		/aa =\			
Revenue (%)	(14.0)	(23.5)	10.7	6.7	6.7
Operating EBITDA (%)	(30.1)	(53.8)	20.2	11.4	8.6
Operating EBIT (%)	(32.7)	(61.3)	22.1	12.8	9.2
Recurring EPS (%)	(33.9)	(62.4)	24.3	14.5	9.7
Reported EPS (%)	(33.9)	(62.4)	24.3	14.5	9.7
Operating performance					
Gross margin inc. depreciation (%)	41.5	26.0	27.4	28.4	28.9
Gross margin exc. depreciation (%)	45.3	31.7	33.3	34.2	34.7
Operating EBITDA margin (%)	39.1	23.6	25.6	26.7	27.2
Operating EBIT margin (%)	35.3	17.9	19.7	20.8	21.3
Net margin (%)	27.5	13.5	15.2	16.3	16.7
Effective tax rate (%)	19.8	20.4	20.4	20.4	20.4
Dividend payout on recurring profit (%)	63.3	73.6	60.0	60.0	60.0
Interest cover (X)	349.5	88.7	143.2	(729.4)	(382.9)
Inventory days	18.5	20.8	22.4	22.7	22.6
Debtor days	24.8	38.5	39.1	38.3	35.9
Creditor days	55.9	60.3	59.5	60.2	60.0
Operating ROIC (%)	47.1	15.9	18.4	20.5	22.2
ROIC (%)	45.1	14.9	17.5	19.6	21.3
ROE (%)	36.8	13.9	16.7	17.7	17.9
ROA (%) * Pre-exceptional pre-goodwill and fully diluted	27.4	10.5	13.0	14.2	14.5
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Cash patient revenue	5,160	5,025	5,541	5,993	6,482
SSO patient revenue	2,149	2,461	2,763	2,875	2,990
NHSO patient revenue	2,794	244	256	269	277

Sources: Chularat Hospital; FSSIA estimates

Financial Statements

Chularat Hospital

Chularat Hospital					
Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	2,778	1,046	1,300	1,488	1,632
Depreciation	382	441	503	536	572
Associates & minorities	-	-	-	-	-
Other non-cash items	117	30	22	24	26
Change in working capital	(696)	435	(147)	(43)	(41)
Cash flow from operations Capex - maintenance	2,582 (777)	1,951 (1,451)	1,678 (514)	2,006 (548)	2,188 (585)
Capex - maintenance Capex - new investment	(111)	(1,451)	(314)	(348)	(383)
Net acquisitions & disposals	(142)	19	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(919)	(1,432)	(514)	(548)	(585)
Dividends paid	(2,805)	(1,045)	(770)	(780)	(893)
Equity finance	0	0	(705)	0	0
Debt finance Other financing cash flows	356 (3)	(120) 44	(705) (22)	(24)	(26)
Cash flow from financing	(2,452)	(1,121)	(1,497)	(804)	(919)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	(789)	(601)	(333)	653	685
Free cash flow to firm (FCFF) Free cash flow to equity (FCFE)	1,679.02 2,016.07	543.33 443.25	1,181.99 436.94	1,459.48 1,432.98	1,605.58 1,577.12
Free cash now to equity (FCFE)	2,010.07	443.23	430.94	1,432.90	1,077.12
Per share (THB)					
FCFF per share	0.15	0.05	0.11	0.13	0.15
FCFE per share Recurring cash flow per share	0.18 0.30	0.04 0.14	0.04 0.17	0.13 0.19	0.14 0.20
	2000	2222	22215	2225	22225
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross)	7,867	9,318	9,831	10,379	10,964
Less: Accumulated depreciation Tangible fixed assets (net)	(2,987) 4,880	(3,414) 5,903	(3,917) 5,914	(4,453) 5,926	(5,025) 5,939
Intangible fixed assets (net)	4,000	104	104	104	104
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	142	122	122	122	122
Cash & equivalents	2,001	1,399	1,066	1,719	2,404
A/C receivable	757	874	960	960	960
Inventories Other current assets	265	336	364	383	405
Current assets	2,036 5,058	1,436 4,046	1,590 3,980	1,697 4,759	1,811 5,580
Other assets	152	88	88	88	88
Total assets	10,280	10,264	10,209	11,000	11,834
Common equity	7,523	7,525	8,054	8,762	9,501
Minorities etc.	341	406	406	406	406
Total shareholders' equity	7,864 470	7,931 705	8,461 0	9,168 0	9,908 0
Long term debt Other long-term liabilities	233	705 247	247	247	247
Long-term liabilities	704	953	247	247	247
A/C payable	851	894	966	1,017	1,077
Short term debt	400	45	45	45	45
Other current liabilities	462	442	490	522	558
Current liabilities	1,712	1,381	1,501	1,584	1,679
Total liabilities and shareholders' equity Net working capital	10,280 1,745	10,264 1,311	10,209 1,458	11,000 1,500	11,834 1,542
Invested capital	6,967	7,529	7,687	7,741	7,796
* Includes convertibles and preferred stock which is beir		.,020	.,00.	.,	1,100
Per share (THB)					
Book value per share	0.68	0.68	0.73	0.80	0.86
Tangible book value per share	0.68	0.67	0.72	0.79	0.85
Financial strength					
Net debt/equity (%)	(14.4)	(8.2)	(12.1)	(18.3)	(23.8)
Net debt/total assets (%)	(11.0)	(6.3)	(10.0)	(15.2)	(19.9)
Current ratio (x)	3.0	2.9	2.7	3.0	3.3
CF interest cover (x)	198.7	29.9	38.3	(549.5)	(289.5)
Valuation	2022	2023	2024E	2025E	2026E
Recurring P/E (x) *	11.4	30.3	24.4	21.3	19.4
Recurring P/E @ target price (x) *	15.4	41.0	33.0	28.8	26.3
Reported P/E (x) Dividend yield (%)	11.4 5.6	30.3 2.4	24.4 2.5	21.3 2.8	19.4 3.1
Price/book (x)	4.2	4.2	3.9	3.6	3.1
Price/tangible book (x)	4.2	4.3	4.0	3.7	3.4
EV/EBITDA (x) **	7.8	17.3	14.2	12.5	11.2
EV/EBITDA @ target price (x) **	10.7	23.4	19.3	17.1	15.5
EV/invested capital (x)	4.4	4.2	4.0	3.9	3.8
* Pre-exceptional, pre-goodwill and fully diluted ** EBI	ITDA includes associate i	income and recurr	ing non-operating i	ncome	

Sources: Chularat Hospital; FSSIA estimates

Chularat Hospital PCL (CHG TB)



Exhibit 4: FSSIA ESG score implication

38.25 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 5: ESG – peer comparison

	FSSIA		Domestic ratings					Global ratings						Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
всн	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Υ	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 6: ESG score by Bloomberg

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	_	2.21	2.34
BESG environmental pillar score	_	_	4.04	4.18
BESG social pillar score	_	_	0.74	0.79
BESG governance pillar score	_	_	4.19	4.49
ESG disclosure score	36.82	36.82	41.54	50.24
Environmental disclosure score	16.49	16.49	17.67	32.92
Social disclosure score	12.70	12.70	19.41	30.29
Governance disclosure score	81.10	81.10	87.36	87.36
Environmental				
Emissions reduction initiatives	Yes	Yes	Yes	Yes
Climate change policy	No	No	Yes	Yes
Climate change opportunities discussed	No	No	No	No
Risks of climate change discussed	No	No	No	No
GHG scope 1	0	0	0	0
GHG scope 2 location-based	4	4	4	4
GHG Scope 3	1	1	1	1
Carbon per unit of production	_	_	_	_
Biodiversity policy	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes
Total energy consumption	_	_	_	_
Renewable energy use	_	_	_	_
Electricity used	4	4	4	7
Fuel used - natural gas	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 7: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 202
Fuel used - crude oil/diesel	No	No	No	N
Waste reduction policy	Yes	Yes	Yes	Ye
Hazardous waste	0	0	0	
Total waste	1	1	1	
Waste recycled	0	0	0	
Waste sent to landfills	_	_	_	-
Environmental supply chain management	No	No	No	N
Water policy	No	No	Yes	Υe
Water consumption	89	73	80	7
Social				
Human rights policy	Yes	Yes	Yes	Ye
Policy against child labor	Yes	Yes	Yes	Ye
Quality assurance and recall policy	No	No	No	١
Consumer data protection policy	Yes	Yes	Yes	Ye
Equal opportunity policy	Yes	Yes	Yes	Ye
Gender pay gap breakout	No	No	No	١
Pct women in workforce	_	_	84	8
Pct disabled in workforce	_	_	_	
Business ethics policy	Yes	Yes	Yes	Y
Anti-bribery ethics policy	Yes	Yes	Yes	Υ
Health and safety policy	Yes	Yes	Yes	Y
Lost time incident rate - employees	_	_	_	
Total recordable incident rate - employees	_	_	_	
Training policy	Yes	Yes	Yes	Y
Fair remuneration policy	No	No	No	1
Number of employees – CSR	3,612	3,616	3,871	4,5
Employee turnover pct	_	_	20	:
Total hours spent by firm - employee training	_	_	32,904	85,88
Social supply chain management	No	No	No	١
Governance				
Board size	12	12	12	•
No. of independent directors (ID)	4	4	4	
No. of women on board	2	2	2	
No. of non-executive directors on board	11	11	11	
Company conducts board evaluations	Yes	Yes	Yes	Υ
No. of board meetings for the year	6	7	7	
Board meeting attendance pct	100	100	95	1
Board duration (years)	3	3	3	
Director share ownership guidelines	No	No	No	1
Age of the youngest director	60	62	63	
Age of the oldest director	77	78	79	
No. of executives / company managers	6	6	6	
No. of female executives	2	2	2	
Executive share ownership guidelines	No	No	No	ı
Size of audit committee	3	3	3	
No. of ID on audit committee	3	3	3	
Audit committee meetings	5	5	5	
Audit meeting attendance %	100	100	100	1
Size of compensation committee	5	5	5	
No. of ID on compensation committee	4	4	4	
No. of compensation committee meetings	2	2	2	
Compensation meeting attendance %	100	100	83	1
Size of nomination committee	5	5	5	
No. of nomination committee meetings	2	2	2	
Nomination meeting attendance %	100	100	83	1
Sustainability governance				
Verification type	No	No	No	1

 $Sources: Bloomberg; FSSIA's \ compilation$

Disclaimer for ESG scoring

ESG score	Methodolog	у			Rating					
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process bas from the ann	ed on the com	transparent, rules-based npanies' Total Sustainabil pal Corporate Sustainabili panies within each industr	lity Scores resulting ity Assessment (CSA).	Sustainability A ESG Score of I	Assessment (C ess than 45% ny are disqual	the annual S&P C CSA) for DJSI. Co of the S&P Glob lified. The constitutiverse.	ompanies with al ESG Score	an S&P Global of the highest	
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing but Candidates 1) no irregular float of >150 up capital. S 70%; 2) index wrongdoing	usiness with tr must pass the ar trading of th shareholders come key disque ependent direct related to CG,	ility in Environmental and ransparency in Governance preemptive criteria, with the board members and exs, and combined holding rualifying criteria include: ctors and free float violatic, social & environmental i earnings in red for > 3 year	ce, updated annually. two crucial conditions: xecutives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	To be eligible for THSI inclusion, verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against th nature of the relevant industry and materiality. SETTHSI Index is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks.					
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	the Thai IOD,	th in sustainable developr with support from the Sto Its are from the perspectiv is.	ock Exchange of	Good (80-89), 3 and not rated for equitable treatr	3 for Good (70 or scores belo ment of sharel 25%); 4) disclo	pories: 5 for Excel 0-79), 2 for Fair (6 ow 50. Weightings holders (weight 2 osure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), le rights; 2) and); 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment and transparent and tof five the criteria cover date (45%), circulation of sexercised. The and verifiability	e incorporated and sufficiently and sufficiently are CG componer AGM proced and after the resufficient informate second assessy; and 3) openner	which shareholders' rights d into business operations ly disclosed. All form imponents to be evaluated annotures before the meeting imeeting (10%). (The first a stion for voting; and 2) facilitations for your personal propers for Q&A. The third involveues, resolutions and voting res	s and information is ortant elements of two nually. The assessment (45%), at the meeting ssesses 1) advance ting how voting rights can be neetings; 2) transparency ses the meeting minutes that			o four categories: r (80-89), and not		* /	
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmen policies. The (Companies de Declaration of Certification, in managers and	nt of key contree Certification is eciding to becon Intent to kick off including risk ass	Checklist include corruptions, and the monitoring a is good for three years. The a CAC certified member store at 18-month deadline to subsessment, in place of policy are tablishment of whistleblowing all stakeholders.)	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.						
Morningstar Sustainalytics	based on an risk is unma	assessment on aged. Sources	isk rating provides an ove of how much of a compar is to be reviewed include corp ther media, NGO reports/webs	ny's exposure to ESG porate publications and	more risk is uni	managed, the	score is the sum higher ESG risk	is scored.		
		ompany feedbac uality & peer rev	ck, ESG controversies, issuer views.	feedback on draft ESG	NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+	
ESG Book	positioned to the principle helps explain over-weighti	o outperform o of financial m n future risk-a	sustainable companies th over the long term. The m nateriality including inform djusted performance. Mat ith higher materiality and erly basis.	nethodology considers nation that significantly teriality is applied by	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.					
<u>MSCI</u>	MSCI ESG r	atings aim to	measure a company's mand laggards according to	anagement of financially their exposure to ESG ris	relevant ESG ris	ks and opport they manage	unities. It uses a those risks relat	rules-based n	nethodology to	
	AAA	8.571-10.00		•		-		•		
	AA	7.143-8.570	Leader:	leading its industry in ma	anaging the most si	gnificant ESG ri	sks and opportunitie	ès		
	Α	5.714-7.142	2							
	BBB	4.286-5.713		a mixed or unexceptiona industry peers	al track record of ma	anaging the mos	st significant ESG ris	sks and opportu	nities relative to	
	ВВ	2.857-4.285	_	muusmy peers						
	В	1.429-2.856	6					. ===		
	ccc	0.000-1.428	Laggard: 8	lagging its industry base	d on its high expos	ure and failure t	o manage significan	nt ESG risks		
Moody's ESG solutions	believes that	sesses the deg t a company ir	gree to which companies ntegrating ESG factors int or shareholders over the i	to its business model and						
Refinitiv ESG rating	based on pu	ıblicly available	and objectively measure le and auditable data. The ata publicly. (Score ratings a	e score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	ent degree of t		
S&P Global			ore is a relative score meanin the same industry clas				of ESG risks, op	portunities, ar	id impacts	
Bloomberg	ESG Score		score is based on Bloor	ating the company's aggr mberg's view of ESG fina the weights are determin	incial materiality.	The score is	a weighted gener	ralized mean (power mean)	
				•		, ,				

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
31-Mar-2021 26-Apr-2021 20-May-2021	BUY BUY BUY	3.50 3.90 4.00	05-Aug-2021 09-Feb-2023 03-Aug-2023	BUY BUY BUY	4.70 4.40 3.90	03-Nov-2023 30-Jan-2024	BUY BUY	4.00 3.90

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Chularat Hospital	CHG TB	THB 2.88	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 08-Mar-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.